Treatment of chancroid with azithromycin. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Treatment of chancroid with azithromycin.

Int J STD AIDS. 1996;7 Suppl 1:9-12. Unique Identifier : AIDSLINE MED/96230313
Ballard RC; Ye H; Matta A; Dangor Y; Radebe F; National Reference Centre for Sexually Transmitted Diseases,; South African Institute for Medical Research, Johannesburg, South; Africa.


Abstract: A randomized, comparative study undertaken in Nairobi, Kenya and a non-comparative evaluation undertaken in Carletonville, South Africa have both shown that a single oral dose of azithromycin 1 g is effective in the treatment of the genital ulcer disease (GUD), chancroid, with cure rates of 89% and 92% recorded respectively. While treatment failure was associated with human immunodeficiency virus seropositivity and lack of circumcision in Kenya, no such association could be found in the South African study. In both series, azithromycin treatment resulted in cure of both Haemophilus ducreyi culture-positive and culture-negative cases of GUD, including two cases subsequently diagnosed as lymphogranuloma venereum. A combination of single-dose azithromycin with single-dose benzathine penicillin may provide effective 'single-visit' syndromic treatment for GUD in many developing countries.
Keywords: Antibiotics, Macrolide/*ADMINISTRATION & DOSAGE Azithromycin/*ADMINISTRATION & DOSAGE Chancroid/*DRUG THERAPY Clinical Trials Comparative Study Human HIV Seropositivity Kenya Male Randomized Controlled Trials South Africa Treatment Outcome JOURNAL ARTICLE REVIEW REVIEW LITERATUREKWDantibiotics,macrolide/KWDadministration&dosageazithromycin/KWDadministration&dosagechancroid/KWDdrugtherapyclinicaltrialscomparativestudyhumanhivseropositivitykenyamalerandomizedcontrolledtrialssouthafricatreatmentoutcomejournalarticlereviewreviewliterature
961030
M96A1417

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .